Wolfe Research Downgrades Blueprint Medicines (BPMC) to Peerperform
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wolfe Research analyst Andy Chen downgraded Blueprint Medicines (NASDAQ: BPMC) from Outperform to Peerperform.
For an analyst ratings summary and ratings history on Blueprint Medicines click here. For more ratings news on Blueprint Medicines click here.
Shares of Blueprint Medicines closed at $101.35 yesterday.
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Nomura/Instinet Downgrades Korea Electric Power Corp. (015760:KS) (KEP) to Neutral
- Berenberg Downgrades Inter Parfums (IPAR) to Hold
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
